Loading…
avatar for Ted L. Liberti

Ted L. Liberti

BioMagnetic Solutions
COO, EVP Business Development & co-founder
State College, PA USA
My focus is company formation, life science technology, platforms and keen business development to bring products & systems to market directly and with major biotech, pharma and cell therapy companies.
About BioMagnetic Solutions:
Founded in in 2012, BioMagnetic Solutions manufactures cGMP, ultra-high performance cell selection reagents and systems for CAR-T cell & gene therapy product manufacture. The market for clinical cell selection will reach $1 billion by 2026. In 2019, BioMagnetic Solutions launches its X-GRAFFE™ clinical-scale cell selection system for CAR-T cell & gene therapy product manufacture to provide a much better solution for clinical cell separation. X-GRAFFE™ is a higher performing, faster, easier to use, highly adaptable cell selection system. X-GRAFFE's common-capture, indirect mAb labeling protocols deliver better CGT performance & economics than any competing system.
BioMag's X-GRAFFE™ Clinical-Scale Cell Selection system brings a complete array of cGMP clinical-grade mAbs, cytokines & reagents for CAR-T CGT product manufacture. X-GRAFFE has 5 PCT international patent applications covering X-GRAFFE’s methods, protocols & hardware.
X-GRAFFE™ leverages BioMag's CELLSEARCH® market-tested proprietary 5th-gen immunomagnetic Ferrofluids. Using standard CGT blood bags, BioMag's X-GRAFFE & nano-magnetic ferrofluid cell selection reagents rapidly, yet gently, isolate cell subsets for CAR-T cell manufacture. X-GRAFFE also isolates CD34+ stem cells for GT products & HSCT products.
Founded by Paul A. Liberti, PhD in 2011, BioMag is the successor to Immunicon Corp. (NASDAQ: IMMC) where BioMag's CEO/CSO developed CELLSEARCH® ~ the only FDA-approved circulating tumor cell (CTC) assay marketed & owned by J&J's Janssen unit & acquired by Menarini’s Silicon BioSystems in 2017.
BioMagnetic Solutions brings 30+ years of: innovation, problem-solving, product development, IP & design to BioMag's proprietary 5th-gen ferrite-based nanoparticles (Ferrofluids) & magnetic cell selection devices for the most challenging CGT applications.